New hope for advanced breast cancer: experimental drug combo enters trials
NCT ID NCT07560124
First seen May 02, 2026 · Last updated May 13, 2026 · Updated 3 times
Summary
This early-phase trial tests a new drug called AK138D1, given alone or with another drug (ivonescimab), in 286 people with advanced breast cancer. The main goals are to check safety and see if tumors shrink. Participants must be 18-75, in good enough health, and have at least one measurable tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Contact
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact
Conditions
Explore the condition pages connected to this study.